title: Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1-JAK2 fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target?
authors.forename: Monika
authors.initials: M
authors.lastname: Prochorec-Sobieszek
authors.forename: Barbara
authors.initials: B
authors.lastname: Nasiłowska-Adamska
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Borg
authors.forename: Izabella
authors.initials: I
authors.lastname: Kopeć
authors.forename: Kinga
authors.initials: K
authors.lastname: Kos-Zakrzewska
authors.forename: Przemysław
authors.initials: P
authors.lastname: Juszczyński
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Warzocha
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D049109:Cell Proliferation; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics; D002908:Chronic Disease; D003937:Diagnosis, Differential; D004900:Erythroblasts / Q000473:pathology*; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D017681:Hypereosinophilic Syndrome / Q000175:diagnosis* / Q000188:drug therapy; D007231:Infant, Newborn; D016898:Interferon-alpha / Q000627:therapeutic use; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D011252:Pregnancy Complications, Neoplastic / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D014178:Translocation, Genetic; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D015514:Oncogene Proteins, Fusion; C575876:PCM1-JAK2 fusion protein, human; D006918:Hydroxyurea